Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patriot: AZD6738 in Solid Tumours
NCT02223923Phase 1Active, not recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jul 2014
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceralasertib in solid tumor (4 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Jul 2014; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02223923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223923.